Altogether, these data argue that the increase of KRAS expression observed in KRAS mutant cancers is driven not only by an overall increase in KRAS expression, but by altered splicing favoring an increase in the ratio of KRAS4A to KRAS4B transcripts. The gene discussed is KRAS; the disease is cancer.